Atlas Trials

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Clinical trial NCT05314010 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05314010
Sponsor
Beijing Mabworks Biotech Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Neuromyelitis Optica Spectrum Disorder
Start date
2022-08-18
Primary completion
2025-02-21
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.